- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07288177
Studie for å vurdere effektiviteten og sikkerheten til Rina-S hos deltakere med ikke-småcellet lungekreft (RAINFOL-05)
En fase 2, åpenmerket, flerkohortstudie av Rinatabart Sesutecan (Rina-S) hos deltakere med ikke-småcellet lungekreft
This Phase 2 study will be conducted in different countries around the world with up to about 240 participants.
The purpose of this study is to evaluate how well Rina-S works against lung cancer.
The treatment in this study is Rina-S monotherapy (by itself). All participants will receive active drug; no one will be given placebo.
The treatment duration will be different for every participant, but an average of 12 months is expected. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of cycle is 3 weeks). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open.
Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
This is a Phase 2, open-label, multicenter, multi-cohort trial to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics of Rina-S as monotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC), with or without select genomic aberrations.
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Genmab Trial Information
- Telefonnummer: +4570202728
- E-post: clinicaltrials@genmab.com
Studiesteder
-
-
-
Adelaide, Australia
- Rekruttering
- St Andrews Medical Centre
-
Blacktown, Australia
- Rekruttering
- Blacktown Hospital
-
Camperdown, Australia
- Rekruttering
- Chris O'Brien Lifehouse
-
Fitzroy, Australia
- Rekruttering
- St Vincent's Hospital - Melbourne
-
Hobart, Australia
- Rekruttering
- Icon Cancer Centre Hobart
-
Hyde Park, Australia
- Rekruttering
- Icon Cancer Care - Townsville
-
Hyde Park, Australia
- Rekruttering
- Icon Cancer Centre Townsville ICON Cancer Care - Townsville
-
Kogarah, Australia
- Rekruttering
- St George Hospital
-
Murdoch, Australia
- Rekruttering
- St John of God Murdoch Hospital
-
Nedlands, Australia
- Rekruttering
- Sir Charles Gairdner Hospital
-
Saint Leonards, Australia
- Rekruttering
- GenesisCare North Shore
-
-
-
-
-
Edegem, Belgia
- Rekruttering
- Universitair Ziekenhuis Antwerpen
-
Hasselt, Belgia
- Rekruttering
- Jessa Ziekenhuis - Campus Virga Jesse
-
La Louvière, Belgia
- Rekruttering
- Chu Helora Hospital La Louvière Site Jolimont
-
Leuven, Belgia
- Rekruttering
- UZ Leuven - Gasthuisberg Campus
-
Roeselare, Belgia
- Rekruttering
- AZ Delta (Campus Wilgenstraat)
-
-
-
-
California
-
Fountain Valley, California, Forente stater, 92708
- Rekruttering
- Compassionate Cancer Care Center
-
Irvine, California, Forente stater, 92618
- Rekruttering
- City of Hope Orange County Lennar Foundation Cancer Center
-
San Diego, California, Forente stater, 92108
- Rekruttering
- Kaiser Permanente San Diego Mission Road
-
Santa Rosa, California, Forente stater, 95403
- Rekruttering
- Providence Medical Foundation (St. Joseph Heritage Healthcare)
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forente stater, 20007
- Rekruttering
- MedStar Georgetown University Hospital
-
-
Florida
-
Miami, Florida, Forente stater, 33136
- Rekruttering
- University of Miami Hospital
-
Tampa, Florida, Forente stater, 33612
- Rekruttering
- Moffitt Cancer Center and Research Institute
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Emory Winship Cancer Institute
-
-
Montana
-
Billings, Montana, Forente stater, 59102
- Rekruttering
- St. Vincent Frontier Cancer Center
-
-
Nebraska
-
Lincoln, Nebraska, Forente stater, 68506
- Rekruttering
- Nebraska Hematology-Oncology
-
-
New Jersey
-
East Brunswick, New Jersey, Forente stater, 08816
- Rekruttering
- Astera Cancer Care
-
-
New York
-
Albany, New York, Forente stater, 12206
- Rekruttering
- ONE Onc: New York Oncology Hematology
-
The Bronx, New York, Forente stater, 10461
- Rekruttering
- Montefiore Medical Park
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27514
- Rekruttering
- UNC Health - University of North Carolina
-
-
Oregon
-
Eugene, Oregon, Forente stater, 97401
- Rekruttering
- Williamette Valley Cancer Institute and Research Center
-
Portland, Oregon, Forente stater, 97213
- Rekruttering
- Providence Portland Medical Center
-
West Haven-Sylvan, Oregon, Forente stater, 97225
- Rekruttering
- Providence Oncology & Hematology Care Clinic - Westside
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Tennessee Oncology - Nashville St. Thomas Midtown Clinic
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Tennessee Oncology Nashville - SCRI Oncology Partners
-
-
Texas
-
Dallas, Texas, Forente stater, 75246
- Rekruttering
- Baylor Charles A. Sammons Cancer Center
-
-
Virginia
-
Fairfax, Virginia, Forente stater, 22031
- Rekruttering
- Virginia Cancer Specialists
-
-
-
-
-
Marseille, Frankrike
- Rekruttering
- Assistance Publique Hôpitaux de Marseille - Hôpital Nord
-
Paris, Frankrike
- Rekruttering
- Groupe Hospitalier Paris Saint-Joseph
-
Paris, Frankrike
- Rekruttering
- Cochin Hospital
-
Paris, Frankrike
- Rekruttering
- Institut Curie - Centre de Recherche
-
Pierre-Bénite, Frankrike
- Rekruttering
- Lyon Sud Hospital Center
-
-
-
-
-
Candiolo, Italia
- Rekruttering
- Istituto di Candiolo - IRCCS
-
Meldola, Italia
- Rekruttering
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
-
Orbassano, Italia
- Rekruttering
- Azienda Ospedaliero Universitaria San Luigi Gonzaga
-
Ravenna, Italia
- Rekruttering
- Ospedale Santa Maria delle Croci
-
Roma, Italia
- Rekruttering
- Policlinico Agostino Gemelli
-
-
-
-
-
Chūō, Japan
- Rekruttering
- National Cancer Center - Tsukiji Campus
-
Tokyo, Japan
- Rekruttering
- Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital
-
-
Kanagawa
-
Sagamihara, Kanagawa, Japan
- Rekruttering
- Kitasato University Hospital
-
Yokohama, Kanagawa, Japan
- Rekruttering
- Kanagawa Cardiovascular and Respiratory Center
-
-
Kyoto
-
Kyoto, Kyoto, Japan
- Rekruttering
- Kyoto Prefectural University of Medicine
-
-
Minami Ward
-
Nagoya, Minami Ward, Japan
- Rekruttering
- Japan Community Health Care Organization Chukyo Hospital
-
-
Moroyama
-
Saitama, Moroyama, Japan
- Rekruttering
- Saitama Medical University International Medical Center
-
-
Osaka
-
Sakai, Osaka, Japan
- Rekruttering
- NHO Kinki Chuo Chest Medical Center
-
-
-
-
-
Beijing, Kina
- Rekruttering
- Beijing Cancer Hospital
-
Beijing, Kina
- Rekruttering
- Beijing Chest Tumor Hospital
-
Changchun, Kina
- Rekruttering
- Jilin Provincial Cancer Hospital
-
Nanjing, Kina
- Rekruttering
- Nanjing Medical University (NMU) - Jiangsu Province Hospital (First Affiliated Hospital)
-
Tianjin, Kina
- Rekruttering
- Tianjin Medical University Cancer Institute and Hospital
-
Zhangjiakou, Kina
- Rekruttering
- The First Affiliated Hospital of Hebei North University
-
Zhengzhou, Kina
- Rekruttering
- Henan Cancer Hospital
-
-
Pudong
-
Shanghai, Pudong, Kina
- Rekruttering
- Shanghai East Hospital
-
-
-
-
-
Amsterdam, Nederland
- Rekruttering
- The Netherlands Cancer Institute (NKI)
-
Leiden, Nederland
- Rekruttering
- Leids Universitair Medisch Centrum
-
Nijmegen, Nederland
- Rekruttering
- Radboudumc
-
-
-
-
-
Gdansk, Polen
- Rekruttering
- Gdański Uniwersytet Medyczny
-
Krakow, Polen
- Rekruttering
- KOMED Roman Karaszewski I Wspolnicy Spolka Jawna
-
Lodz, Polen
- Rekruttering
- Instytut MSF
-
Poznan, Polen
- Rekruttering
- MedPolonia
-
-
-
-
-
A Coruña, Spania
- Rekruttering
- Hospital Teresa Herrera
-
Barcelona, Spania
- Rekruttering
- Parc de Salut Mar - Hospital del Mar
-
Barcelona, Spania
- Rekruttering
- USP Instituto Universitario Dexeus
-
Barcelona, Spania
- Rekruttering
- Hospital Germans Trias i Pujol
-
Las Palmas de Gran Canaria, Spania
- Rekruttering
- Hospital Universitario Insular de Gran Canaria
-
Logroño, Spania
- Rekruttering
- START Rioja
-
Madrid, Spania
- Rekruttering
- Hospital Universitario 12 de Octubre
-
Madrid, Spania
- Rekruttering
- Hospital General Universitario Gregorio Marañón
-
Madrid, Spania
- Rekruttering
- Hospital Universitario Fundación Jiménez Díaz
-
Madrid, Spania
- Rekruttering
- MD Anderson Cancer Center Madrid
-
Madrid, Spania
- Rekruttering
- Clinica Universidad de Navarra - Madrid
-
Málaga, Spania
- Rekruttering
- Hospital Quirón Málaga
-
Pamplona, Spania
- Rekruttering
- Clinica Universidad de Navarra - Pamplona
-
Valencia, Spania
- Rekruttering
- Fundación IVO. Instituto Valenciano de Oncología
-
Valencia, Spania
- Rekruttering
- Hospital Clinico Universitario de Valencia
-
-
-
-
-
Cheongju-si, Sør -Korea
- Rekruttering
- Chungbuk National University Hospital
-
Daegu, Sør -Korea
- Rekruttering
- Keimyung University Dongsan Hospital
-
Incheon, Sør -Korea
- Rekruttering
- Gachon University Gil Medical Center
-
Seoul, Sør -Korea
- Rekruttering
- Korea University Anam Hospital
-
Suwon, Sør -Korea
- Rekruttering
- The Catholic University Of Korea St. Vincent's Hospital
-
-
-
-
-
Changhua, Taiwan
- Rekruttering
- Changhua Christian Hospital
-
Kaohsiung City, Taiwan
- Rekruttering
- Kaohsiung Medical University Chung-Ho Memorial Hospital
-
New Taipei City, Taiwan
- Rekruttering
- Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare
-
Tainan, Taiwan
- Rekruttering
- Chi Mei Medical Center - Liouying
-
Tainan, Taiwan
- Rekruttering
- National Cheng Kung University
-
Taipei, Taiwan
- Rekruttering
- National Taiwan University Hospital (NTUH)
-
-
-
-
-
Berlin, Tyskland
- Rekruttering
- Evangelische Lungenklinik Berlin
-
Essen, Tyskland
- Rekruttering
- Universitaetsklinikum Essen
-
Halle, Tyskland
- Rekruttering
- Krankenhaus Martha-Maria Halle-Dölau
-
Heidelberg, Tyskland
- Rekruttering
- Thoraxklinik-Heidelberg
-
-
-
-
-
Kecskemét, Ungarn
- Rekruttering
- Bács-Kiskun Megyei Kórház - Kecskemét
-
Tatabánya, Ungarn
- Rekruttering
- Szent Borbála Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
- Participant has histologically or cytologically confirmed metastatic or locally advanced NSCLC of adenocarcinoma histology, not amenable to curative surgery or radiotherapy.
- Participant must have radiological disease progression while on or after receiving the most recent regimen.
- Participants either may have actionable genetic alterations (AGAs) or no AGAs.
- Participant has measurable disease according to RECIST v1.1.
- Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1 within 7 days of Cycle 1 Day 1.
Key Exclusion Criteria (all study cohorts):
- Participant has NSCLC with histology other than adenocarcinoma
- Participant has a past or current malignancy other than the inclusion diagnosis before the planned first dose of trial treatment, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death (eg, 5-year OS ≥ 90%), including, but not limited to, adequately treated cervical carcinoma of stage 1B or less, in situ basal cell or squamous cell skin carcinoma, in situ bladder cancer, ductal carcinoma in situ, or any past malignancy considered cured for ≥ 3 years.
- Participants with newly identified or known unstable (eg, progressing brain metastases) or symptomatic central nervous system (CNS) metastases or history of carcinomatous meningitis (also known as leptomeningeal disease). Participants with history of spinal cord compression (from disease). Participants with previous CNS-directed therapy (eg, radiotherapy and/or surgery) for brain metastases may participate provided lesion(s) are radiologically stable (ie, without evidence of progression) for at least 28 days by repeat imaging.
Note: Other protocol-defined Inclusion and Exclusion criteria may apply.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Rina-S
Multiple cohorts (Cohorts A, B, C, D, and E) will receive Rina-S as monotherapy. |
Intravenous (IV) infusion.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Objektiv responsrate (ORR) i henhold til Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 som vurdert av forskeren
Tidsramme: Omtrent 3 år
|
Omtrent 3 år
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Varighet av respons (DOR) per RECIST v1.1 vurdert av undersøker
Tidsramme: Omtrent 4 år
|
Omtrent 4 år
|
|
Sykdomskontrollrate (DCR) per RECIST v1.1 vurdert av undersøker
Tidsramme: Omtrent 4 år
|
Omtrent 4 år
|
|
Progresjonsfri overlevelse (PFS)
Tidsramme: Omtrent 4 år
|
Omtrent 4 år
|
|
Generell overlevelse (OS)
Tidsramme: Omtrent 4 år
|
Omtrent 4 år
|
|
Maksimal (topp) observert serumkonsentrasjon (Cmax) av Rina-S-relaterte analytter
Tidsramme: Omtrent 12 måneder
|
Omtrent 12 måneder
|
|
Tid til å nå maksimal (topp) serum legemiddelkonsentrasjon (Tmax) av Rina-S-relaterte analyser
Tidsramme: Omtrent 12 måneder
|
Omtrent 12 måneder
|
|
Antall deltakere med antistoffer mot legemiddelet (ADAer)
Tidsramme: Omtrent 12 måneder
|
Omtrent 12 måneder
|
|
Antall deltakere med behandlingsrelaterte bivirkninger (TEAE)
Tidsramme: Omtrent 4 år
|
Omtrent 4 år
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Study Official, Genmab
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- GCT1184-05
- 2025-522107-18-00 (Ctis)
- jRCT2041250176 (Registeridentifikator: Japan Registry for Clinical Trials (jRCT))
- CTR20260819 (Registeridentifikator: Chinadrugtrials.org.cn)
- 2025 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .